Loading
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Previous close
$0.7212
+$0.0208 · +2.97%
Regular session · ET · Market data may be delayed.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Day range
Current $0.7212
52-week range
Current $0.7212
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
97
Deep Value
Sentiment
46
Mixed
Risk
66
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Day range
Current $0.7212
52-week range
Current $0.7212
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 53.43M USD | 25.38M USD | — | — | — |
| Cost of goods sold | 3.75M USD | 1.62M USD | — | — | — |
| Gross profit | 49.68M USD | 23.77M USD | — | — | — |
| Research and development | 38.31M USD | 137.25M USD | 158.66M USD | 179.21M USD | 182.89M USD |
| Selling, general, and administrative | 66.93M USD | 63.39M USD | 49.13M USD | 47.04M USD | 36.52M USD |
| Operating expenses | 105.24M USD | 200.64M USD | 212.76M USD | 248.03M USD | 226.91M USD |
| Interest income | — | 6.95M USD | — | 6.71M USD | — |
| Interest expense | — | — | — | 43.08M USD | — |
| Depreciation and amortization | 2.11M USD | 3.11M USD | 2.03M USD | 462K USD | 1K USD |
| Operating income | −55.56M USD | −176.88M USD | −212.76M USD | −248.03M USD | −226.91M USD |
| Net income | −52.49M USD | −169.93M USD | −198.64M USD | −241.32M USD | −226.79M USD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$9.50
1217.25% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.43M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM4.07M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2.46M0.00%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO1.16M0.01%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC480.77K0.04%1.32B USD0.60%$183+0.11%
iShares Core S&P Total U.S. Stock Market ETFITOT414.11K0.00%97.48B USD0.03%$169.66+0.64%
Virtus Biotech Clinical Trials ETFBBC288.65K0.70%41M USD0.65%$44.1456+2.08%
Vanguard Russell 2000 Value ETFVTWV186.14K0.01%1.4B USD0.06%$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVirtus Biotech Clinical Trials ETFBBCVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
